Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

ranibizumab (Rx)Brand and Other Names:Lucentis

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

intravitreal injectable solution

  • 6mg/mL (0.05mL [0.3mg/vial])
  • 10mg/mL (0.05mL [0.5mg/vial])
more...

Neovascular (Wet) Age-related Macular Degeneration

0.5 mg intravitreal qMonth

May give q3month after 3 or 4 monthly injections (if continued monthly dosing not feasible) but is less effective than once monthly dosing

Macular Edema

Indicated for macular edema following retinal vein occlusion

0.5 mg intravitreal injection qMonth x6 months

Diabetic Macular Edema

0.3 mg intravitreally qMonth

Diabetic Retinopathy with DME

Indicated for treatment of diabetic retinopathy in patients with diabetic macular edema (DME)

0.3 mg intravitreally qMonth

Does not apply

Next

Interactions

Interaction Checker

ranibizumab and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Conjunctival hemorrhage (43-77%)

            Eye pain (17-37%)

            Vitreous floaters (3-32%)

            Incr IOP (8-24%)

            Vitreous detachment (7-22%)

            Eye irritation (4-19%)

            Intraocular inflammation (5-18%)

            Headache (2-15%)

            Upper resp tract infection (2-15%)

            Retinal disorder (13%)

            Blepharitis (3-13%)

            Retinal degeneration (1-11%)

            1-10%

            Conjunctival hyperemia (9%)

            Posterior capsule opacification (8%)

            Injection site hemorrhage (5%)

            Vitreous hemorrhage (4%)

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity

            Ocular/periocular infections

            Cautions

            Risk of endophthalmitis or retinal detachment with intravitreous injections

            Possibility of IOP increase within 60 min of intravitreal injection

            Potential for adverse thromboembolic events (eg, nonfatal stroke, nonfatal MI, vascular death)

            Temporary visual disturbances may occur

            The incidence of fatal events reported to be higher in diabetic macular edema

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Unknown if distributed in milk; use caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Humanized monoclonal antibody to VEGF-A, inhibits VEGF-A-induced ocular neovascularization

            Pharmacokinetics

            Half-Life: 9 days (vitreous)

            Peak PlasmaTime: 1 day

            Peak Plasma Concentration: 0.3-2.36 ng/mL

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.